TABLE 5.

Phenotypic analysis and prevalence of signature NS5A resistance-conferring amino acid variants relative to baseline by clonal sequencing

Dose QD (mg) and patient	Visit day	EC50 (pM)	Fold resistancea	Treatment-emergent variants at signature resistance-conferring amino acid positions in NS5A (% frequency)b
				Multiple variants	M28		Q30		Y93
					T	V	E	R	C	H	N	S
5
1	3	19.4	41			100
	6	46.2	98		26	31		30
2	3	1.7	2.7			21		8
	6	2.3	3.7			15		6
25
3	3	12.2	18		16	24		37	15
	6	24.5	36		16			52	14
50
4	3	75.8	105		46	22	5	16
	6	254	353		49	13		25	5
5	3	180	219	62c						10		22
	6	333	406	44c						11		39
200
6	6	1,477	2,238		65			22		8
7	3	103	198		18			21	17	19
	6	482	927					40	35	6	6
8	3	963	2,006		34			55		5
	6	892	1,858		40			50	5

^aFold change in EC₅₀ of ombitasvir in samples from day 3 or day 6 relative to the EC₅₀ in the respective baseline sample.

^bVariants observed in ≥5% of the clones are shown.

^cQ30L + Y93H was the major double variant, and Q30L + Y93S was the minor variant.